Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Injectable MPL allergy vaccine - Allergy Therapeutics

Drug Profile

Injectable MPL allergy vaccine - Allergy Therapeutics

Alternative Names: Birch pollen allergen extract; Birch pollen modified allergen tyrosine-absorbed; Grass MATA MPL; Grass pollen modified allergen tyrosine-adsorbed; Pollinex Quattro; Pollinex Quattro Grass; Pollinex Quattro Tree; Pollinex Quattro® Birch; PQ Birch; PQ Grass; Tree MATA MPL

Latest Information Update: 07 May 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Allergy Therapeutics
  • Class Allergy immunotherapies; Antiallergics
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Grass pollen hypersensitivity
  • Phase III Allergic rhinoconjunctivitis
  • Phase II Seasonal allergic rhinitis; Tree pollen hypersensitivity

Most Recent Events

  • 22 Feb 2019 Updated efficacy data from a phase II trial in Allergic rhinoconjunctivitis presented at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI-2019)
  • 20 Jun 2018 Allergy Therapeutics completes a phase III trial in Allergic rhinoconjunctivitis (Prevention) in Sweden, Germany, Poland and Austria (SC) (EudraCT2016-002781-31)
  • 21 May 2018 Efficacy data from a phase II trial in Allergic rhinoconjunctivitis released by Allergy Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top